Nantahala Capital Management LLC Makes New Investment in Viemed Healthcare, Inc. $VMD

Nantahala Capital Management LLC acquired a new position in shares of Viemed Healthcare, Inc. (NASDAQ:VMD) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 632,445 shares of the company’s stock, valued at approximately $7,209,873. Nantahala Capital Management LLC owned 1.66% of Viemed Healthcare at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in VMD. BlackRock Inc. bought a new position in shares of Viemed Healthcare in the second quarter worth $54,587,000. Wasatch Advisors LP boosted its position in Viemed Healthcare by 18.4% in the second quarter. Wasatch Advisors LP now owns 1,546,010 shares of the company’s stock valued at $10,683,000 after buying an additional 240,346 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Viemed Healthcare by 3.6% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,447,033 shares of the company’s stock valued at $10,751,000 after acquiring an additional 49,962 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Viemed Healthcare by 2.0% during the second quarter. Geode Capital Management LLC now owns 798,515 shares of the company’s stock worth $5,519,000 after purchasing an additional 15,353 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its holdings in Viemed Healthcare by 101.9% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 711,186 shares of the company’s stock worth $6,550,000 after acquiring an additional 358,863 shares during the last quarter. 74.24% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on VMD. Wall Street Zen cut Viemed Healthcare from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 15th. Weiss Ratings downgraded shares of Viemed Healthcare from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, August 17th. Freedom Capital lowered Viemed Healthcare from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 5th. Finally, Barrington Research initiated coverage on shares of Viemed Healthcare in a report on Monday, August 24th. They issued an “outperform” rating and a $14.00 price target for the company. One investment analyst has rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $14.00.

Viemed Healthcare Stock Performance

NASDAQ VMD opened at $8.82 on Friday. The company has a fifty day moving average price of $10.83 and a 200-day moving average price of $9.89. The firm has a market cap of $335.95 million, a price-to-earnings ratio of 24.50, a PEG ratio of 2.22 and a beta of 1.10. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.13 and a quick ratio of 1.02. Viemed Healthcare, Inc. has a 1 year low of $6.05 and a 1 year high of $12.61.

Viemed Healthcare (NASDAQ:VMD) last released its quarterly earnings results on Monday, August 3rd. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.05). Viemed Healthcare had a net margin of 4.81% and a return on equity of 10.16%. The firm had revenue of $78.10 million for the quarter, compared to the consensus estimate of $78.00 million. As a group, equities research analysts predict that Viemed Healthcare, Inc. will post 0.41 EPS for the current fiscal year.

Insider Activity

In other news, insider William Frazier sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $11.72, for a total value of $117,200.00. Following the completion of the transaction, the insider directly owned 73,214 shares of the company’s stock, valued at $858,068.08. This represents a 12.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Timothy Smokoff sold 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $11.50, for a total value of $230,000.00. Following the completion of the transaction, the director directly owned 75,518 shares of the company’s stock, valued at approximately $868,457. This represents a 20.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 20.60% of the company’s stock.

Viemed Healthcare Profile

Viemed Healthcare, Inc (NASDAQ: VMD) is a provider of home-based respiratory therapy services, specializing in the management of patients requiring long-term mechanical ventilation and pulmonary support. The company’s offerings encompass invasive and noninvasive ventilation, airway clearance therapies, cough assist devices, and supplemental oxygen. Viemed combines durable medical equipment with clinical care, delivering tailored respiratory treatment plans that are overseen by licensed respiratory therapists and registered nurses.

Founded in the early 2010s and headquartered in Birmingham, Alabama, Viemed has grown its footprint to serve patients across multiple states in the United States.